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ABSTRACT
Background: To examine occurrence of cow’s milk protein intolerance (CMPI) in newborns that underwent
small intestine surgery and the clinical profiles of those newborns with postoperative CMPI, and to evaluate the
preventive effects of probiotics on CMPI.
Methods: We retrospectively reviewed from 2000 to 2009, a total of 30 newborns required surgery on their
small intestines. All of these patients had received antibiotics to prevent postoperative infection. Since 2005 we
adopted a protocol of targeted probiotic therapy prophylaxis.
Results: Eighteen patients received probiotic therapy, while twelve did not. One infant among those eighteen
patients and eight patients among those twelve developed CMPI, a significantly lower rate for the group with
probiotic therapy than that without it (p < 0.001). Patients with positive cultures for gram positive and gram
negative organisms increased in number before and after surgery but then decreased after probiotics treat-
ment. Poor weight gain, gastrointestinal symptoms, and rise in C reactive protein (CRP) levels were observed
in all of those nine CMPI patients. Specific IgE antibodies were elevated in four of the nine subjects, and total
IgE levels were elevated in seven of them. All CMPI patients had increased level of CRP without proven infec-
tions.
Conclusions: CMPI was induced in newborns after surgery on their small intestines and antibiotics treatment
with presentation of symptoms that mimic postoperative infection. Development of CMPI in this population pos-
sibly involves disruption of intestinal flora. Administration of probiotics can reduce the incidence of CMPI after
small intestine surgery. The elevated CRP level may be useful in the diagnosis of CMPI.
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INTRODUCTION
Intestinal microbial flora plays important roles in
their host organism. They can defend against patho-
genic bacteria, mediate interactions between bacteria
present in the intestines and contribute to gastroin-
testinal immunity.1 Therefore, it is essential for new-
borns to acquire flora to gain mature intestinal immu-
nity.
Normal development of intestinal flora can be dis-
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rupted by antibiotic therapy, which may cause abnor-
mal immune function. When Oyama, et al., adminis-
tered oral antibiotics to newborn mice, their intestinal
flora was disrupted, Th2 cell dominant responses
were induced and allergies were developed.2 Estab-
lishment of immune tolerance to food antigens in-
gested orally has been blocked in adult mice when in-
testinal flora was removed at the age of their new-
borns (germ-free mice).3 When intestinal flora is dis-
rupted or a delay occurs in acquiring normal intesti-
nal flora, gastrointestinal immune functions do not
mature, resulting in food intolerance.
Intestinal flora begins to develop immediately after
birth and is fully formed within 2 days to a week.4
Newborns who require surgery on the small intestine
soon after birth are subject to various conditions that
can hinder them from acquiring intestinal flora. One
of the problems is the delayed start of nutrition. How-
ever, the major problem of surgery concerning the ef-
fect on intestinal flora is the administration of antibi-
otics to prevent postoperative infections, because the
existing flora can easily disrupted by the use of sys-
temic antibiotics.5
Bifidobacterium breve (B. breve) is used for probi-
otic treatment in neonates. B. breve can colonize the
immature bowel of humans very effectively, and it is
associated with fewer abnormal abdominal signs and
better weight gain in newborns.6 B. brebe is used in
newborns to prevent neonatal necrotizing enterocoli-
tis.7 For these reasons we have administered B. breve
routinely to neonates after gastrointestinal surgery
since 2005 under permission from the ethics commit-
tee of our university.
Based on our experience we considered that some
newborns who undergo small intestine surgery de-
velop intolerance to cow’s milk protein, because they
have not acquired intestinal flora or their existing in-
testinal microbial colonization is disrupted. Then we
hypothesized that intolerance against cow’s milk pro-
tein could be prevented by administering B. breve.
The purpose of the present retrospective study was
two-fold. Our first objective was to examine onset of
cow’s milk protein intolerance (CMPI) in newborns
who underwent small intestine surgery, and the pre-
ventive effects of B. breve on the onset of milk intoler-
ance. The second objective was to clarify the clinical
profile of newborns with postoperative milk intoler-
ance.
METHODS
We retrospectively reviewed the charts of infants who
were admitted to the Neonatal Intensive Care Unit
(NICU) at Saitama Medical Center at Saitama Medi-
cal University who underwent surgery of the small in-
testine between January 2000 and December 2009.
We identified all infants who had surgery on the
small intestine and used the discharge database
(search keywords ‘small intestine’ or ‘surgery’) to de-
termine further eligibility. The study was approved
by the Institutional Review Board of the Human In-
vestigation Committee of Saitama Medical University,
and informed consent was received from all of the
participants.
TREATMENT PROTOCOL AFTER SURGERY OF
THE SMALL INTESTINE
In our NICU we have implemented a standardized
treatment protocol after small intestine surgery; cefo-
taxime sodium (CefotaxTM, Sanofiaventis, Tokyo, Ja-
pan) and gentamaicin sulfate (GentacinTM, MSD, To-
kyo, Japan) are the first line therapy for prevention of
post-operative infection. Antibiotics were adminis-
tered until white blood cell counts and CRP values re-
turned to normal values after surgery. The normal
CRP value for a newborn is less than 1 mgdL. Com-
plete blood count and CRP tests are performed rou-
tinely at least twice each week, while samples are
taken three or four times each week if abnormal val-
ues are noted.
The surgeon and attending physician checked
clinical findings of bowel peristalsis, flatulence, disap-
pearance of bile from gastric aspiration and defeca-
tion.
X-ray findings included disappearance of postop-
erative ileus and intestinal swelling, and uniform gas-
trointestinal gas distribution. When both physicians
judged that nutrition could be initiated, enteric feed-
ing was begun after confirming good gastrointestinal
motility on a gastroenterogram.
Mother’s milk was basically given as enteric nutri-
ent, unless otherwise it was not available, formula
was given. The initial amounts given were 1, 3 or 5 ml
each time for birth weights of <1, <1.5 or greater than
1.5 kg, respectively. Feeding was done every 3 hr af-
ter aspiration of gastric contents. Feeding amounts
were increased once a day by the same amount as the
initial one when the total amount of gastric residuals
was less than 10% of the total amount of milk or for-
mula given in the previous day. Feeds may have been
withheld if there was abdominal distention, vomiting
or repeated large amount of gastric aspirates. Par-
enteral nutrition was ceased when full oral feeds
reached the amount of 100 mlkgday. These meth-
ods were not changed throughout the ten years of
study period.
PROBIOTIC THERAPY
Since January 2005 we adopted a protocol of targeted
probiotic therapy prophylaxis for all infants after
small intestine surgery who were at risk for intestinal
hypoperistalsis, detrimental intestinal flora, malfunc-
tioning gastrointestinal tract, invasive bacterial infec-
tion and necrotizing enterocolitis until full enteral
feeding (100 mlkgday) is reached.
A probiotic (B. breve M-16V; Morinaga Milk Indus-
try, Tokyo, Japan) was administered simultaneously
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Table　1　Comparison of newborns who did and did not receive probiotic therapy after small intestine surgery
Probiotics (+)
n = 18
Probiotics (-)
n = 12 p-value
Gestational age, weeks 34.5 (23.5-38.4) 34.4 (26.4-40.0) 0.67
Birth weight, g 1978 (296-3646) 2004 (542-3522) 0.82
Age at surgery, days 4 (0-64) 1.5 (0-16) 0.13
Disease requiring surgery
Small intestinal atresia 12 10 0.42
Localized intestinal perforation  6  2
Surgical procedure
Development of fi stulae 11  6 0.71
Anastomosis  7  6
Nutrition
Age after surgery when enteral feeding was initiated, days 7.5 (3-13) 6.0 (3-10) 0.06
Type of nutrition
Breast milk  7  5 1.0
Breast milk and formula or Artifi cial milk 11  7
Family history of allergic disease 2 (11) 2 (17) 1.0
Cases of milk intolerance 1 (6) 8 (67) <0.001
Data are shown as median (range) or n (%).
with either breast milk or infant formula. B. breve (1 ×
109 cells in a package of 1 g) was suspended in 2 mL
of sterilized water and 0.5 mL (2.5 × 108 B. breve) of
the suspension was administered enterally 3 times a
day (7.5 × 108 cellsday). We adopted the dosage of
B. breve determined and reported by Kitajima, et al..6
As for the newborns who were treated with prophy-
lactic probiotic therapy, stool cultures were obtained
before surgery, before the commencement of, and a
week after the probiotic therapy was completed.
DIAGNOSIS OF CMPI
We diagnosed CMPI with respect to the guidelines
from Europe8 and Japan.9 By those guidelines, CMPI
is diagnosed when; symptoms disappear after two
doses of milk with eliminated cow’s milk protein;
other digestive disorder of the lactose intolerance
and the infection, etc were excluded; and recurrence
of identical symptoms were noted after one challenge
of normal formula.
Based on the diagnostic standards of food allergy
in Europe8 and Japan9 in our facility, we first sus-
pected CMPI from symptoms such as weight loss,
weight gain, lethargy, abdominal distension, vomit-
ing, decreased feeding intake, diarrhea and bloody
stool.
Next, we conducted various allergy tests including
peripheral eosinophil count, a level of total immuno-
globulin E, a level of specific IgE antibodies (against
cow’s milk, α-lactalbumin, β-lactoglobin, and casein),
fecal eosinopil, and other tests such as blood count,
biochemical screening, C reactive protein (CRP) val-
ues, stool culture, X-ray examination, and Clinitest.
Using the results of these tests, we eliminated milk if
all other diseases other than CMPI were ruled out.
We often experience the patients with CMPI accom-
panied with the rise of CRP values which resembles
postoperative infection.
The milk protein tolerance test was performed af-
ter the patient was fasted in order to eliminate milk
protein and two weeks after symptoms relieved. Dur-
ing the fasting period, nutrition was managed by par-
enteral nutrition. There are no unified opinion con-
cerning particular method of milk protein tolerance
test for newborn, such as the amount of milk to give
and time interval of milk feeds. Therefore, we con-
ducted the tests using formulas or mother’s milk
which contains the same milk protein which patients
were given when they expressed the symptoms that
were suspected of CMPI, with different loading doses
by bodyweight. With respect to the nutrition manage-
ment protocol for post small intestine operation in
our facility, initial loading dose were assigned accord-
ing to body weight at the time when milk protein tol-
erance test was performed. For bodyweight of less
than 1 kg, 1 ml (<1 mlkgdose), for 1-1.5 kg, 1.5 ml
(1-1.5 mlkgdose), and for over 1.5 kg, 5 ml (<3.3
mlkgdose) were the initial loading dose. The loads
were given 8 times per day and the amounts were
doubled every day.
These diagnostic standards were similar to those of
“Food Protein-Induced Enterocolitis Syndrome: Con-
sensus Recommendations for Diagnosis and Treat-
ment” (Japanese Research Group for Neonatal, Infan-
tile Allergic Disorders; http:www.nch.go.jpimal
FPIESFPIES_eng.pdf). However, the milk-specific
lymphocyte stimulation responses recommended by
this research group required a large quantity of blood
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Table　2　Fecal culture of newborns who received probiotic therapy after small intestine surgery
Pathogens Before operation Before probiotics treatment After probiotics treatment
Gram positive organisms 9 19 13
Enterococcus spp. 2 (11) 5 (28) 4 (22)
Corynebacterium spp. 2 (11) 4 (22) 1 (6)
Stapylococcus-coagulase-negative 5 (28) 8 (44) 8 (44)
Staphylococcus aureus (MRSA) 0 (0) 2 (11) 0 (0)
Gram negative organisms 1  9  2
Escherichia coli 1 (6) 3 (17) 1 (6)
Klebsiella spp. 0 (0) 4 (22) 1 (6)
Acinetobacter spp. 0 (0) 1 (6) 0 (0)
Pseudomonas spp. 0 (0) 1 (6) 0 (0)
Fungi 0  3  2
Candida spp. 0 (0) 3 (17) 2 (11)
Two or more types of pathogens 4 (22) 9 (50) 6 (33)
Free of pathogens 13 (72) 2 (11) 6 (33)
n (%). Numbers for gram positive organisms, gram negative organisms, and fungi include those with multiple pathogens.
collection, and since the intestinal mucosal biopsy is
invasive, it could not be performed.
Eosinophilia is defined in neonates as an eosinophil
count 700 cellsmm3 and has been further sub-
classified as mild (700 to 999 cellsmm3), moderate
(1000 to 2999 cellsmm3), or severe (>3000 cells
mm3).10,11
STATISTICAL ANALYSIS
Software of SPSS 14.0 J (SPSS, Chicago, IL, USA)
was used to generate summary statistics (mean, stan-
dard deviation, median and range values) for clinical
variables. A group of patients with CMPI without pro-
biotic therapy was compared with the group who
used probiotic therapy by the Mann-Whitney U test.
Proportions and continuous variables were compared
using Fisher’s exact two-tailed test.
RESULTS
DEMOGRAPHICS
Among all infants screened, 30 required surgery on
their small intestine. 12 infants in the group with pro-
biotic treatment and 18 infants in the group without
probiotic treatment were included during this study.
No differences in baseline demographics were noted.
But, as for the initiation of the milk feeding, non pro-
biotic group tended to be earlier (p = 0.06, Table 1).
INCIDENCE OF CMPI AND EFFICACY OF PROBI-
OTIC THERAPY
One infant among those eighteen patients who re-
ceived probiotics and eight infants out of twelve that
did not developed CMPI, a significantly lower rate for
the patients with probiotic therapy than those without
probiotic therapy (Table 1, p < 0.001). No adverse ef-
fect such as bacteremia, sepsis, and infection with an-
aerobic bacteria were observed in patients who were
given probiotics.
The number of neonates who had positive stool
cultures for either of gram positive or gram negative
organisms or both increased after surgery before pro-
biotics treatment was started, but decreased after a
week of probiotics treatment. Moreover, after initia-
tion of probiotics therapy, the number of patient with
negative culture increased from two to six (Table 2).
CHARACTERISTICS OF CMPI PATIENTS
Clinical symptoms, including poor weight gain and
gastrointestinal symptoms such as diarrhea and
bloody stool, were observed in all of nine milk intoler-
ance subjects. All patients except patient # 2 did not
use probiotics (Table 3). CMPI was diagnosed at the
time range of 4 to 61 days (median 31) after the start
of enteric nutrition.
Among 8 patients who did not use probiotics and
diagnosed as CMPI, two patients, patients #4 and #8,
were fed by breast milk, patient #3 was fed by artifi-
cial formula and other 5, patients #1, 5, 6, 7 and 9
were fed by both breast milk and formula. On the
other hands, patient #2 who had probiotics but estab-
lished CMPI was fed by both breast milk and formula
(Table 3).
IgE levels specific for major bovine milk proteins
as well as total IgE were elevated in four patients di-
agnosed as CMPI including patient #2. Other three
infants had increased levels of total IgE but had no
rise of IgE specific for major bovine milk antigens
tested (Table 3).
Although CMPI was suspected, the total IgE values
in both the samples negated in the food tolerance test
were less than 2 kUL, that is, below the detection
sensitivity.
All patients with CMPI increased CRP values with-
out aberrant value of white blood cell count and ratios
Probiotics Reduce Milk Intolerance
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of bands to segment forms were also within normal
range.
DISCUSSION
The incidence of CMPI among newborns has been
reported previously as 2-5%.12 In this present study,
newborns who received small intestine surgery and
antibiotics showed a high incidence (67%) of CMPI
when they were not given probiotic treatment. How-
ever, incidence of CMPI became 6% by prophylactic
probiotic administration. This incidence rate of CMPI
is similar to that for the patients without operation.
In a similar research, milk hypersensitivity inci-
dence rate after gastrointestinal tract surgery re-
ported by EL. Hassani13 was 4.3%, which was evi-
dently lower than the CMPI incidence rate of 67% ob-
served in our research in cases where probiotics
were not used. The reason for this could be that the
concept of post gastrointestinal tract surgery milk hy-
persensitivity is just not prevalent in France, as
pointed out in the thesis by EL. Hassani, as well as in
many other countries. The second reason could be
the difference in target organs. Our research only
dealt with post small intestinal surgery cases,
whereas theirs targeted post gastrointestinal tract
surgery of stomach, small intestine, and large intes-
tine.
Another possible reason is the presence of allergic
colitis, along with neonatal necrotizing enterocolitis
(NEC) and CMPI in inflammatory intestinal mucosal
lesions occurring in neonatals.14 Interestingly, there
have been very few cases of NEC incidence in Japan
as compared to other countries.15 From the fact that
the symptoms of CMPI are very similar to the symp-
toms of NEC, probably CMPI is included in the diag-
nostic symptoms of NEC in other countries, and that
Japan is more prone to suspecting CMPI as com-
pared to other countries. Moreover, one of the trig-
gers of NEC is bacterial infection. The variation in the
use of antibiotics in Japan and other countries may be
decreasing the incidence rate of NEC while increas-
ing the incidence of CMPI. In either of the cases,
there is variation in the data of inflammatory gastroin-
testinal mucosal lesions in Japan and other countries,
requiring more research.
Oral tolerance is defined as a state of immunologi-
cal unresponsiveness to a specific antigen after expo-
sure to that antigen.16 It is now widely accepted that
mechanisms of oral tolerance include anergy, apopto-
sis (deletion) of exogenous antigen-specific T cells in
the gut and active suppression through induction of
exogenous antigen-specific regulatory T cells. IL-10-
and TGF-β-producing regulatory T cells play impor-
tant roles in maintaining intestinal homeostasis.17
The microbiota in the gut can play an important role
in generating fully functional regulatory T cells.18 The
possibility that B. breve can help inhibiting inflamma-
tion and controlling the onset of allergies has been
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predicted, because it induces TGF-β1 and adjusts the
balance between Th1 and Th2 cells.19 Immune toler-
ance to food antigens ingested orally has not been es-
tablished in mice with treatment to eliminate intesti-
nal flora in neonatal period.3
In the present investigation the high incidence of
milk intolerance in newborns who did not receive
probiotic therapy appeared to be due to direct surgi-
cal invasion to the intestines. It has been reported
that milk intolerance is apt to occur after colorectal
surgery.13 Surgery of small intestine results in keep-
ing the intestinal immune system away from food an-
tigens for particular period of time, possibly loosing a
chance to induce oral tolerance to food antigens,
some of which are milk antigens for infants. In addi-
tion, we assumed that colorectal surgery disrupted
their intestinal flora, leading to CMPI. Use of antibiot-
ics delayed the start of enteric nutrition and may have
disrupted intestinal flora without inducing oral toler-
ance by anergy or apoptosis of exogenous antigen-
specific T cells or activation of regulatory T cells, as
described previously.17
Conversely, newborns who were given probiotics
showed normal or strengthened intestinal immunity
and improved oral tolerance to milk, most likely be-
cause the profile of microbiota in their gastrointesti-
nal tract was rectified. Patients with positive cultures
for gram positive and gram negative organisms in-
creased in number before and after surgery but then
decreased after probiotics treatment (Table 2). From
the fact that probiotics are known to be efficient in
improving the microbial environment in the gastroin-
testinal tract, there is a possibility that improvement
of the intestinal environment by administration of
probiotics may improve the incidence rate of CMPI.
Furthermore, in animal experiments, the probiotic
MV16 used in this research was found to posses an-
tiallergic properties,20 which may helped to inhibit
the incidence of CMPI.
A recent randomized study showed that supple-
menting extensively hydrolyzed formula with probiot-
ics does not decrease cow’s milk intolerance in in-
fants with milk allergy.21 In that study,21 probiotics
was given after they were diagnosed of CMPI. How-
ever, in this study we applied probiotics before the di-
agnosis of CMPI was made. Probiotics may be effec-
tive not for treatment of, but prevention from develop-
ing CMPI. Also probiotic therapy probably had pre-
ventive effects on intolerance only in newborns with
disrupted intestinal flora such as newborn treated
with antibiotics.
B. breve was used in the present study because this
bacteria is derived from human neonatal intestine
and its bacterial translocation ability was extremely
low compared with other probiotic bacteria.22 No ad-
verse reactions, such as sepsis, have been reported in
the use of B breve. This bacterium is considered very
safe for use in probiotic treatment. No adverse reac-
tions were observed in any of the newborns in the
present study.
The symptoms of CMPI in newborns are usually
gastrointestinal and the mechanism of food allergy is
independent of IgE.9 However, it has been shown
that patients allergic to cow’s milk had serum IgE
specific for bovine milk proteins.23 In the present
study, the symptoms were also mainly gastrointesti-
nal. IgE, RAST, eosinophil counts and neutrophil
counts in the feces were examined in all subjects with
CMPI. It was interesting that IgE antibodies specific
for milk components were elevated in four of nine
subjects. At the time of CMPI diagnosis, out of the 5
cases where there was no rise in specific IgE antibod-
ies, there was 1 case with positive milk-specific IgE
antibodies when evaluated at 2 months (patient #5).
In our hospital the total IgE is less than 5 kUL in
normal newborns. In this study the total IgE was 5
kUL or higher in seven of nine patients with milk in-
tolerance. When the intestinal flora of newborns was
disrupted by antibiotics, increase in the production of
IgE occurs,2 and so we can speculate this response
may contribute to form milk intolerance.
Except for 2 samples of eosinophil count, which is
a factor in the determination of CMPI, the samples
were classified between moderate to severe. The 2
samples classified as mild also showed values close to
moderate (Table 2).
What makes the result even more interesting is
that the patient of all CMPI showed the rise of CRP
level. It has been reported that the amount of IL-6 in
the duodenum increases with the development of
CMPI,24 and we herein focused our attention on its
mediator, CRP.25,26 Serum CRP is easier to measure
than IL-6, with the advantage that it takes a shorter
time to obtain the test results. Rise in serum CRP can
be used as one of a supportive factor in diagnosis of
CMPI.
In conclusion, CMPI was induced in newborns af-
ter small intestine surgery and it is possible that dis-
ruption of intestinal flora is involved. Administration
of B. breve reduced the incidence of CMPI after small
intestine surgery. In the NICU, efforts should be
made to improve intestinal flora in consideration of
the risk of onset of CMPI after small intestine sur-
gery. The measurement of CRP level seems to be ef-
fective for the diagnosis of CMPI.
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